C ommunity-acquired pneumonia (CAP) is the sixth leading cause of death in the United States 1 and the third in Chile. 2 Between 5% and 15% of hospitalized patients present with severe CAP that must be treated in an ICU. Complications are frequent, hospital stay is prolonged, and mortality varies between 21% and 54%. 3, 4 Background: In US and European literature, Legionella pneumophila is reported as an important etiologic agent of severe community-acquired pneumonia (CAP), but in Chile this information is lacking. The aim of this study was to determine the incidence and identify predictors of severe CAP caused by L pneumophila in Santiago, Chile. Methods: A multicenter, prospective clinical study lasting 18 months was conducted; it included all adult patients with severe CAP admitted to the ICUs of four hospitals in Santiago. We excluded patients who were immunocompromised, had been hospitalized in the previous 4 weeks, or presented with another disease during their hospitalization. All data for the diagnosis of severe CAP were registered, and urinary antigens for L pneumophila serogroup 1 were determined. 
and progression of infi ltrates of Ն 50% within the fi rst 72 h were recorded. The chest radiograph was evaluated by radiologists, but they were not involved in the study. Assessment of illness severity in these patients was performed according to the following scores: Pneumonia Severity Index (PSI), 22 CURB-65 (confusion of new onset, urea . 7 mmol/L [19 mg/dL], respiratory rate Ն 30/min, systolic BP , 90 mm Hg or diastolic BP Յ 60 mm Hg, age Ն 65 y), 23 APACHE (Acute Physiology and Chronic Health Evaluation) II, 24 Sepsis-related Organ Failure Assessment (SOFA), 25 and Pitt Bacteremia Score (PBS). 26 
Microbiology
The microbiologic evaluation on admission included Gram staining and culture of sputum or tracheobronchial aspirates. Two sets of blood cultures were also taken. The detection of L pneumophila serogroup 1 and S pneumoniae antigens by means of an immunochromatographic test (BinaxNOW; Alere) in nonconcentrated urine samples was performed. Aspirated nasopharyngeal secretions for detection of respiratory virus antigens were obtained (test to detect infl uenza A and B, parainfl uenza 1-3, adenovirus, and respiratory syncytial virus) and tested with an indirect immunofl uorescence assay kit with monoclonal antibodies (Chemicon/EMD Millipore Corporation). Serum IgM antibody detection for Mycoplasma pneumoniae and Chlamydophila pneumoniae was performed (RIDASCREEN; R-Biopharm AG). Bacteriologic study of pleural fl uid and BAL and a search for Mycobacterium tuberculosis or IgM and IgG for hantavirus was performed according to clinical judgment. The IgM and IgG antibodies for hantavirus were confi rmed with enzyme-linked immunosorbent assay according to the guidelines of the Centers for Disease Control and Prevention. The antigens used were Laguna Negra virus, Andes virus, or both for IgM and Sin Nombre virus, Andes virus, or both for IgG. Respiratory samples were considered representative of lower respiratory tract infection and cultured if . 25 leukocytes and , 10 epithelial cells were present.
Defi nitions
Any antibiotic use within 30 days of admission was considered a previous treatment. Antibiotic treatment used for each patient was labeled as adequate if sensitivity tests for the isolated organism revealed that at least one of the drugs was effective. In the case of Pseudomonas aeruginosa , two active drugs were required for treatment. An antimicrobial treatment failure in patients with CAP was defi ned according to a prior publication. 27 For predictors observed in the patients with severe CAP from L pneumophila , clinical and laboratory data were compared with that of patients with nonLegionella severe CAP.
Statistical Analysis
Results are expressed as mean Ϯ SD. Continuous variables were compared by Student t test and categorical variables by x 2 or Fisher exact test. To identify factors associated with the presence of L pneumophila severe CAP, we used a logistic regression model with categorized variables and stepwise forward selection. Variables were included in a multivariate analysis when a univariate analysis yielded a level of signifi cance of P , . 10 . The following variables were tested: APACHE II score, SOFA score, and hyponatremia, pH, creatinine, and BUN levels. Results of multivariate analysis are reported as ORs. All tests of signifi cance were two tailed, and a was set at 0.05. All analyses were performed with SPSS, version 12.0 (IBM Corporation) software.
The four hospitals used the same criteria and methods, and their ethics committee approved the study (Hospital del Tórax, 1707/02, and University of Chile, 67/04). Because no intervention was performed, informed consent was waived by institutional review boards.
CAP, Legionella pneumophila is recognized worldwide as another important agent. [7] [8] [9] [10] Geographic and seasonal differences are frequently found in the reported incidence of Legionnaires' dis ease in CAP, which ranges from 2% to 27%. 11, 12 In the United States, it is estimated that the yearly occurrence of CAP is between 8,000 and 18,000 new cases. 13, 14 In 2009, the reported number of US legionellosis cases was 3,522. 15 The diagnosis of legionellosis with bacteriologic isolation of L pneumophila is diffi cult and has low sensitivity; direct immunofl uorescence test is operator dependent, and with low sensitivity and seroconversion, it permits only a retrospective diagnosis. The introduction of the urinary antigen test has improved the etiologic diagnosis of legionellosis. 11, [13] [14] [15] [16] [17] As information regarding Legionella severe CAP in Chile is insuffi cient, our fi rst aim was to determine through a prospective study the incidence of L pneumophila etiology in a general population with severe CAP requiring intensive care. Because prompt diagnosis and specifi c treatment are expected to reduce mortality from Legionella CAP (reported in 21%-40% of patients with CAP), 8, 14, [18] [19] [20] most guidelines, including Chilean consensus, recommend covering both, 3, 11, 21 but this approach is not universally applied. Therefore, we also looked for clinical or laboratory characteristics present at admission that could be identifi ed as early predictors of Legionella etiology, prompting the addition of specifi c antibiotic therapy.
Materials and Methods
From January 1, 2005, to June 31, 2006, we performed a prospective, multicenter clinical study in four hospitals (one university hospital and three from the Public National Health System) in Santiago, Chile. All consecutive inmunocompetent patients aged . 18 years hospitalized for CAP in an ICU in accordance with American Thoracic Society criteria 3 were considered. The diagnosis of CAP was made in the presence of a new infi ltrate on chest radiography and at least one of the following criteria: fever (temperature, Ն 38°C), cough, production of purulent sputum, pleuritic pain, leukocytosis or leukopenia, and no alternative diagnosis made during follow-up. Exclusion criteria were hospitalization during the 28 days preceding the study, inmunosuppression, solid organ or bone marrow transplantation, known HIV infection, neutropenia , 1 3 10 9 /L, treatment with steroids with . 20 mg prednisone or equivalent per day for . 2 weeks, and treatment with immunosuppressive drugs.
The following variables were recorded: age; sex; smoking, alcohol, and drug habits; comorbidities; antibiotic treatment before admission; onset of pneumonia; clinical symptoms; vital signs; CBC count; sedimentation rate; plasma electrolyte, BUN, plasma creatinine, C-reactive protein, and lactic dehydrogenase levels; arterial blood gases and pH measurements; and antibiotic regimen initially prescribed. Mechanical ventilation requirements, complications during ICU stay (pulmonary abscess, pleural empyema, nosocomial pneumonia, ARDS, renal insuffi ciency, septic shock, and multiorgan failure), length of ICU stay, and 28-day mortality rate were also recorded.
Chest radiography fi ndings were classifi ed into one of the following patterns: alveolar, interstitial, or mixed infi ltrate. Bilateral or multilobar infi ltrates, presence of cavitation or pleural effusion, and Staphylococcus aureus (3%). In four patients, two concomitant pathogens were isolated ( S pneumoniae plus M pneumoniae , S pneumoniae plus Haemophilus species, S pneumoniae plus S aureus , and S pneumoniae plus infl uenza A), and in one patient, four bacteria were present (Streptococcus viridans plus three anaerobic bacilli). Table 2 shows the diagnostic procedures used to identify the different microorganisms.
In 14 patients, a pleural empyema developed, and in six of them (43%), the etiology was identifi ed ( S pneumoniae in four, b -hemolytic Streptococcus in one, and S viridans plus anaerobes in one). All isolated strains of S pneumoniae from six blood cultures were susceptible to penicillin.
Determination of urinary antigens of L pneumophila and S pneumoniae was performed in 104 (100%) and 69 patients (66%), respectively. The urine antigen was obtained 0.72 Ϯ 1.5 days after ICU admission. The urinary antigens allowed for the identifi cation of etiology in 26.9% of the patients, improving diagnostic yield over other techniques from 32.7% to 59.6%. A more extensive use of this test for S pneumoniae could lead to a higher diagnostic yield.
Antimicrobial Therapy
Of the 104 patients studied, 29% received antibiotic treatment before admission. Five of these patients with L pneumophila received antibiotic treatment, but the therapy covered the pathogen in only one patient. In this group, the yield of blood cultures was low compared with that of patients without previous antibiotics (4.2% vs 10.7%).
Antibiotic therapies were started at hospital admission (0.11 Ϯ 0.37 days). Among all patients with severe CAP, the initial treatment covered atypical pathogens in only 56%. However, initial antibiotic therapy was adequate in 84% of patients with an ultimately estab- Overall, 42 patients (40%) had antimicrobial treatment failure. Causes were primary infection (n 5 5), defi nite persistent infection (n 5 8), nosocomial infection (n 5 7), noninfectious causes (n 5 2), and pleural empyema (n 5 14).
Severe CAP From L pneumophila Compared With Other Causes of CAP
When comparing patients with severe CAP from L pneumophila with that from other causes, no differences were detected in age, symptoms, physical signs, or chest radiographic fi ndings. APACHE II and
Results
Of 120 patients with severe CAP, 104 were included in the study. The reasons for exclusion from the analyses were as follows: HIV infection (n 5 4), cardiac insuffi ciency (n 5 3), alveolar hemorrhage (n 5 2), bronchiolitis obliterans organizing pneumonia (n 5 2), highdose corticosteroids (n 5 2), pulmonary embolism (n 5 1), atelectasis (n 5 1), and previous hospitalization (n 5 1).
The mean age was 58.2 years (range, 19-89 years); 64.4% were men. Eighty patients (76.9%) had preexisting medical conditions, including pulmonary disease in 44 (42.3%), diabetes in 21 (20.4%), alcohol abuse in 19 (18.4%), and congestive heart failure in 17 (16.5%). The clinical characteristics of the population analyzed are summarized in Table 1 .
Microbiology
A microbiologic diagnosis of pneumonia was established in 62 patients (59.6%). The top seven most frequently identifi ed pathogens were S pneumoniae (26%), L pneumophila (8.6%), M pneumoniae (6%), C pneumoniae (4%), gram-negative bacilli (3%), infl uenza A (3%), 24 16.7 Ϯ 6.3 SOFA score 25 6. an independent predictor for L pneumophila etiology in severe CAP (OR, 11.3; 95% CI, 2.5-50.5; P 5 .001).
Outcome
Stay in the ICU was signifi cantly longer for L pneumophila (13.38 Ϯ 9.1 days vs 3.7 Ϯ 5.4 days, P 5 .02) as was hospital stay, but this was not signifi cant (23.3 Ϯ 9.9 days vs 15.3 Ϯ 11.3 days, P 5 .057). Global mortality at 28 days in severe CAP was 25% and that of L pneumophila was 33.3% (three of nine cases), but the difference was not signifi cant with non-Legionella severe CAP mortality (33% vs 24.5%; P 5 .55). PBS and PSI were better predictors of mortality ( Table 5 ). It must be pointed out that the L pneumophila cases occurred sporadically and were not part of a cluster or outbreaks.
Discussion
The main fi ndings in this study of severe CAP are that (1) in Santiago, Chile, the incidence of L pneumophila in the ICU as the etiologic agent was 8.6%, PSI scores were higher in L pneumophila cases, but the difference was not signifi cant (18.4 Ϯ 3.3 vs 16.6 Ϯ 6.5 and 147 Ϯ 34 vs 126 Ϯ 48, respectively). In contrast, SOFA scores were signifi cantly higher for L pneumophila (8.4 Ϯ 2.4 vs 5.9 Ϯ 3.2, P 5 .024). Levels of BUN, creatinine, and plasma sodium Յ 130 mEq/L on admission showed signifi cant differences between L pneumophila and other pneumonias ( Table 3 ) .
All L pneumophila cases were associated with acute respiratory failure, and all required invasive mechanical ventilation, whereas only 39% of the rest did ( P , .0001). Shock (eight of nine vs 45 of 95 patients, P 5 .031), acute renal failure (eight of nine vs 34 of 95 patients, P 5 .003), and multiple organ failure (six of nine vs 16 of 95 patients, P 5 .003) were also more frequent in L pneumophila severe CAP ( Table 4 ) . Three L pneumophila cases required dialysis, but only four in all the other pneumonias did ( P 5 .003).
Multivariate Analysis
Regression logistic analysis showed that plasma sodium concentration Յ 130 mEq/L on admission was 
Data are presented as counts. GNB 5 gram-negative bacteria; IFA 5 indirect inmunofl uorescence assay on a nasopharyngeal sample; RSV 5 respiratory syncytial virus; TBA 5 tracheobronchial aspirate. See Table 1 mophila in Argentina 37 has been 3.5% and in Brazil, 38 5.1%. We believe that the present study could be of interest in the region and contributes to the knowledge of the epidemiology of L pneumophila . In other international studies, 7-10,39-43 L pneumophila is, as in the present study, an important agent for severe CAP after S pneumoniae. Real incidence of this agent is probably greater with use of the urinary antigen test. In a systematic review and meta-analysis, Shimada et al 44 found that Legionella urinary antigen for serotype 1 appears to have excellent specifi city (0.991) but a moderate sensitivity (0.74). In addition, Legionella urinary antigen only identifi es serogroup 1, which represents 50% to 90% of the Legionella species. 14, 30, 45 These patients presented with different combinations of the clinical manifestations reported for Legionnaires' disease. 18, 46, 47 We could not fi nd any clinical or radiologic variables reported in the literature that differentiated Legionella from other agents in severe CAP. 8, 29, 31 Nevertheless, multivariate analysis showed that severe hyponatremia was an independent predictor of Legionella etiology, which agrees with literature reporting that hyponatremia occurs more frequently in Legionnaires' disease than in other types of pneumonia. 28, 30, 46, 47 We believe that this fi nding is clinically useful in the sense that hyponatremia on admission for severe CAP warrants a prompt search for Legionella etiology with the best available diagnostic methods or, at least, starting the patient on Legionella -active antibiotics.
L pneumophila appears to cause more severe disease with multisystem dysfunction than most common bacterial pathogens associated with CAP. 47 Respiratory failure, particularly when the patient requires intubation and invasive mechanical ventilation, has been second only to S pneumoniae , and (2) severe hyponatremia at admission is an independent predictor of L pneumophila etiology. To our knowledge, this study is the fi rst to examine the incidence of L pneumophila in severe CAP in Chile. The incidence of Legionella species as a cause of sporadic CAP reported in the literature shows differences in the severity of clinical presentation and population considered and different geographical and seasonal data. But the most frequent level has been around 3% to 6%, 12, [28] [29] [30] and in severe CAP, the incidence is greater (5%-24%). 31 The incidence of L pneumophila severe CAP found in the present study is similar to other reports in the literature. 32 These results seem to be generalizable to other countries. 33 The problem of Legionella is that if one does not search specifi cally for it, its existence is neglected. However, we do not know whether this incidence is the same in countries with climates much colder than Chile. A study by the German Competence Network for Community Acquired Pneumonia 30 found an incidence of 3.8%. It is important that all countries have good epidemiologic data of Legionella to release guidelines and treatment recommendations.
In a national study in Santiago that used diagnostic techniques other than the urinary antigen test, Trucco et al 34 reported an 8.5% incidence of L pneumophila in 140 hospitalized patients with CAP. In a retrospective study, Cabello et al 35 reported eight cases of severe CAP as a result of L pneumophila . Díaz et al 36 did not identify L pneumophila in any of 113 cases of severe CAP in their study, but urinary antigens were measured in only 11% of the patients.
In Latin America, we have little information on the epidemiology of Legionella . The incidence of L pneu- Data are presented as proportion (%) unless otherwise indicated. See Table 1 legend for expansion of abbreviations.
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associated with increased mortality. 48 In the present study, clinical evolution of L pneumophila CAP was more severe than the other etiologies. Rapidly progressive respiratory failure and the need for invasive mechanical ventilation were observed in all the patients. Acute renal insuffi ciency needing hemodialysis was frequent, and SOFA score was high, indicating more involved organs. Similar to other reports, mortality from L pneumophila was higher. 8, 18, 20, 48 As a secondary result, we observed that use of the urinary antigen test meant a better diagnostic yield than other usual diagnostic methods and had the advantages of not being invasive, being easy to perform, and yielding rapid results, thus, improving the specifi city of treatment. Additionally, the test for L pneumophila remains positive for weeks and is useful in patients who received previous antibiotic therapy.
Prompt diagnosis of Legionnaires' disease as well as initiation of appropriate therapy can decrease length of stay and the mortality rate. 14, 49 A delay in starting appropriate therapy for Legionella pneumonia significantly increases mortality. 50 The limitations of this study were that it covers the population of only two of the four zones of Santiago and that we used only one diagnostic technique for identifying L pneumophila serogroup 1. Thus, it is possible that the incidence was higher.
In summary, this prospective multicenter study reveals that L pneumophila , with an incidence of 8.6%, is second only to S pneumoniae as an agent for serious CAP in Santiago, Chile, and that hyponatremia is a useful independent predictor for this etiology. Thus, these fi ndings confi rm the guideline that atypical pathogens, particularly L pneumophila , should be covered in addition to pneumococcus by empirical therapy.
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